Analysis Of Medication Rules And Mechanisms In Obesity Combined With Polycystic Ovary Syndrome Based On Data Mining And Network Pharmacolog

Purpose: Based on data mining and network pharmacology technology,the prescription drugs of traditional Chinese medicine for the treatment of obesity complicated with polycystic ovary syndrome(PCOS)were analyzed,and the target and mechanism of action of core drug components in the treatment of obesity combined with polycystic ovary syndrome were predicted at the microscopic level,which provided medical evidence for the research direction of traditional Chinese medicine in the treatment of obesity and polycystic ovary syndrome.Method: Through searching the relevant literature of traditional Chinese medicine in the treatment of obesity complicated with polycystic ovary syndrome published in CNKI,Wanfang and Weipu databases from January 2002 to November 2022.The literature that met the inclusion criteria and exclusion criteria was screened and sorted out,and the database of obesity combined with polycystic ovary syndrome was constructed,and mining tools such as Excel 2019,SPSS Modeler 18.0 and SPSS Statistics 22.0 were used to sort out the frequency of use,sexual taste,efficacy,association rules,cluster analysis of traditional Chinese medicines used in clinical treatment,and visually displayed them.The active ingredients and targets of core drugs were screened out in the database of the TCM System Pharmacology Database and Analysis Platform(TCMSP),and protein genes were standardized through the protein sequence database(Uniprot).Identify the disease targets of obesity combined with polycystic ovary syndrome in the Gene Cards database;The common targets of the drug group and the disease were analyzed,and the PPI network analysis of the common targets was performed in the STRING database,and sorted out by Cytoscape 3.7.2 software;GO enrichment analysis and KEGG enrichment analysis were performed in the Metascape database to visualize the results.Results:1.A total of 75 prescriptions were included in this study,including a total of 153 traditional Chinese medicines,among which the top ten flavors with the highest frequency of use were:Cangzhu,Fuling,Chenpi,Banxia,Baizhu,Dodder seed,Incense,Angelica,Hawthorn,and Danshen.The sexual taste is mostly warm,cold,flat,bitter,sweet and spicy.It is mostly attributed to the liver,spleen,kidney,and lung meridians.The efficacy of the drug is mostly deficiency medicine,blood circulation and stasis removal medicine and antipyretic medicine.In the association rule,set the support ≥ 20% and the confidence level ≥80%,and combine the results of the drug group with the highest support and confidence in the two,three,and four association rules to determine the core drug group as "Chenpi-Cang zhu-Banxia-Fuling-Incense".Cluster analysis of 25 flavors of Chinese medicines with drug frequency ≥12 showed that there were 4 groups of potential new formulas:1 group:Chenpi,banxia,Cangzhu,Incense,Dall southern star,Epimedium,Poria,Danshen;Group 2: Baizhu,Astragalus,Lotus Leaf,Calamus,Hawthorn,Zeeland;Group 3: Shu dihuang,Dogwood,Dodder seeds,Goji berries,Antlers;Group 4: Red peony,Peach kernel,Angelica,Chuanxiong,Iicorice,Citrus husk.2.Through network pharmacology research,a total of 158 targets were screened out with the intersection of "Chenpi-Cang zhu-Banxia-Fuling-Incense" and obesity combined with polycystic ovary syndrome,and 5 core targets were screened out by topological analysis:AKT1,IL6,TNF,TP53,VEGFA.GO enrichment assays enriched in 2035 entries for biological components(BP),182 items for molecular function(MF),and 117 items for cellular processes(CC).BP involves responses to xenogenic stimuli,responses to hormones,responses to inorganic substances,cellular responses to organic cyclic compounds,etc.MF involves DNA binding,transcription factor binding,protein domain-specific binding,kinase binding,protease binding,etc.CC involves membrane rafts,transcriptional regulatory complexes,endoplasmic reticulum lumens,vesicle cavities,etc.KEGG obtained 237 pathways,mainly including IR signaling pathway,AGE-RAGE signaling pathway in diabetes complications,PI3K-Akt signaling pathway,chemical carcinogenic-reactive oxygen species,IL-17 signaling pathway,fox O signaling pathway,NF-k B signaling pathway,ovarian steroid production,AMPK signaling pathway,etc.Conclusion:1.Traditional Chinese medicine treatment of obesity combined with polycystic ovary syndrome should be treated from the liver,spleen,kidney and lungs,and drugs with the effect of replenishing deficiency,activating blood circulation and removing stasis and clearing heat should be selected in medication.The medicinal properties are mainly warm,cold and flat,and the medicinal taste is mostly bitter,sweet and spicy.In clinical practice,Chenpi-Cang zhu-Banxia-Fuling-Incense are often used as the core drug group for dialectical treatment.The new formula is used to treat phlegm,spleen,kidney tonic and blood revitalization,which is consistent with the pathogenesis theory of the disease and can be applied and verified clinically.2.The active ingredients in the core drug group are treated by acting on AKT1,IL6,TNF,TP53,VEGFA and other targets.It also plays a role in obesity combined with polycystic ovary syndrome in terms of anti-inflammatory,regulating insulin resistance,regulating ovarian cell metabolism,improving glycolipid metabolism,inhibiting autophagy,and oxidative stress.